Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas.

Scepansky E, Othman M, Smith H.

Acta Haematol. 2014;131(4):213-7. doi: 10.1159/000353525. Epub 2013 Nov 28.

PMID:
24296552
2.

Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.

Karger R, Weippert-Kretschmer M, Budde U, Kretschmer V.

Blood Coagul Fibrinolysis. 2011 Mar;22(2):144-7. doi: 10.1097/MBC.0b013e328342486a.

PMID:
21178586
3.

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.

Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z.

Best Pract Res Clin Haematol. 2001 Jun;14(2):401-36. Review.

PMID:
11686107
4.

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.

Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, Eisert R, Ganser A, Budde U.

J Thromb Haemost. 2008 Apr;6(4):569-76. doi: 10.1111/j.1538-7836.2008.02909.x. Epub 2008 Jan 17.

5.

A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.

Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia Cattini M, Daidone V, Szukowska M, Pagnan A.

Thromb Haemost. 2007 Dec;98(6):1182-7.

PMID:
18064311
6.

Clinical significance of inhibitors in acquired von Willebrand syndrome.

Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T.

Blood. 1998 May 15;91(10):3623-9. Erratum in: Blood 1999 Jan 1;93(1):413.

7.

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.

Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P.

Thromb Haemost. 2010 Sep;104(3):563-70. doi: 10.1160/TH10-01-0027. Epub 2010 Jun 29.

PMID:
20589313
8.

Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.

Frontroth JP, Hepner M, Sciuccati G, Feliú Torres A, Pieroni G, Bonduel M.

Thromb Haemost. 2010 Dec;104(6):1158-65. doi: 10.1160/TH10-04-0213. Epub 2010 Oct 12.

PMID:
20941465
9.

Laboratory diagnosis and molecular classification of von Willebrand disease.

Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.

Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Review.

PMID:
19506352
10.

Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.

Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. Review.

PMID:
17164493
12.

An update on type 2B von Willebrand disease.

Mikhail S, Aldin ES, Streiff M, Zeidan A.

Expert Rev Hematol. 2014 Apr;7(2):217-31. doi: 10.1586/17474086.2014.868771. Epub 2014 Feb 12. Review.

PMID:
24521271
13.

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.

PMID:
15166918
14.

Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.

Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Semin Thromb Hemost. 2005 Nov;31(5):577-601. Review.

PMID:
16276467
15.
16.

Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.

Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA; Association of Hemophilia Clinic Directors of Canada.

Thromb Haemost. 2002 Feb;87(2):224-30.

PMID:
11858481
17.

Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.

Qin HH, Xing ZF, Wang XF, Ding QL, Xi XD, Wang HL.

Blood Cells Mol Dis. 2014 Apr;52(4):181-5. doi: 10.1016/j.bcmd.2013.11.005. Epub 2013 Dec 16.

PMID:
24351655
18.

A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers.

Ozeki M, Kunishima S, Kasahara K, Funato M, Teramoto T, Kaneko H, Fukao T, Kondo N.

Thromb Res. 2010 Feb;125(2):e17-22. doi: 10.1016/j.thromres.2009.08.012. Epub 2009 Sep 8. Erratum in: Thromb Res. 2010 Oct;126(4):360.

PMID:
19740526
19.

A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry.

Chen D, Daigh CA, Hendricksen JI, Pruthi RK, Nichols WL, Heit JA, Owen WG.

J Thromb Haemost. 2008 Feb;6(2):323-30. Epub 2007 Nov 20.

20.

Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.

Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.

Thromb Haemost. 2007 Jun;97(6):922-30.

PMID:
17549293

Supplemental Content

Support Center